Product Pipeline


See our product candidates and the clinical trial programs sponsored by Karuna Therapeutics.

Product candidates by development phase

Karuna Therapeutics’ development pipeline explores novel treatments for people living with psychiatric and neurological conditions.

Karuna's product pipeline

Product Candidate: KarXT (xanomeline-trospium) M1-M4 muscarinic agonist
Indication: Schizophrenia psychosis
Trial Phase: Phase 3

Product Candidate: KarXT (xanomeline-trospium) M1-M4 muscarinic agonist
Indication: Schizophrenia (adjunctive) psychosis in adults with inadequate response to standard of care
Trial Phase: Phase 3

Product Candidate: KarXT (xanomeline-trospium) M1-M4 muscarinic agonist
Indication: Psychosis in Alzheimer’s disease
Trial Phase: Phase 3

Product Candidate: KAR-2618* TRPC4/5 inhibitor
Indication: Mood & anxiety disorders
Trial Phase: Phase 1

Product Candidate: KAR-201 muscarinic-targeted drug candidate
Indication: Undisclosed
Trial Phase: Preclinical

Product Candidate: KAR-301 muscarinic-targeted drug candidate
Indication: Undisclosed
Trial Phase: Preclinical

Product Candidate: KAR-401 muscarinic-targeted drug candidate
Indication: Undisclosed
Trial Phase: Preclinical

Product Candidate: KAR-501 target-agnostic drug candidate
Indication: Undisclosed
Trial Phase: Preclinical

^In collaboration with PsychoGenics; *Planning stage

Learn more about KarXT

KarXT, the lead product candidate in development at Karuna Therapeutics, is currently being evaluated in Phase 3 clinical trials as both a monotherapy and an adjunctive therapy for the treatment of schizophrenia, as well as for the treatment of psychosis in Alzheimer’s disease. Learn more about KarXT.